Nektar Therapeutics (0UNL.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 709.93M |
| Enterprise Value | 843.72M |
| P/E Ratio | -8.39 |
| PEG Ratio | 6.83 |
| Price/Sales Ratio | 24.82 |
| Price/Book Ratio | 3.03 |
| Enterprise/Revenue | 25.03 |
| Enterprise/EBITDA | -11.06 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | -2.84 |
| Operating Margin | -2.25 |
AD
Management Effectiveness
| Return On Assets | -0.21 |
| Return On Equity | -0.87 |
Income Statement
| Revenue | 55.23M |
| Revenue/Share | 2.25 |
| Gross Profit | 54.21M |
| EBITDA | -133.45M |
| Net Income | -164.08M |
| Diluted EPS | -9.73 |
Balance Sheet
| Total Cash | 568.6M |
| Total Cash/Share | 22.99 |
| Total Debt | 143.43M |
| Total Debt/Equity | 0.25 |
| Current Ratio | 10.21 |
| Book Value Per Share | 23.29 |
Price History
| 52-Week Change | 204.83 |
| 52-Week High | 70.85 |
| 52-Week Low | 69 |
| Moving Average 50 Days | 65.63 |
| Moving Average 200 Days | 62.71 |
Statistics
| Average Volume | 2,144 |
| Shares Outstanding | 19.54M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
